KIN 8741
Alternative Names: KIN-8741Latest Information Update: 08 Apr 2024
At a glance
- Originator Kinnate Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 Apr 2024 Kinnate Biopharma has been acquired by XOMA
- 18 Sep 2023 Kinnate Biopharma expects to file an IND application to the US FDA for Solid tumours, in the fourth quarter of 2023
- 17 Apr 2023 Kinnate Biopharma plans a clinical trial for Solid tumours and Non-small cell lung cancer (Late-stage disease), in the first half of 2024